Edwards Lifesciences - EW Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $94.31
  • Forecasted Upside: 6.91%
  • Number of Analysts: 19
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 13 Buy Ratings
  • 0 Strong Buy Ratings
$88.22
▲ +0.76 (0.87%)

This chart shows the closing price for EW by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Edwards Lifesciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EW and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EW

Analyst Price Target is $94.31
▲ +6.91% Upside Potential
This price target is based on 19 analysts offering 12 month price targets for Edwards Lifesciences in the last 3 months. The average price target is $94.31, with a high forecast of $107.00 and a low forecast of $57.00. The average price target represents a 6.91% upside from the last price of $88.22.

This chart shows the closing price for EW for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 19 contributing investment analysts is to moderate buy stock in Edwards Lifesciences. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 13 buy ratings
  • 5 hold ratings
  • 1 sell ratings
12/1/2022
  • 0 strong buy ratings
  • 13 buy ratings
  • 5 hold ratings
  • 1 sell ratings
3/1/2023
  • 0 strong buy ratings
  • 13 buy ratings
  • 5 hold ratings
  • 1 sell ratings
5/30/2023
  • 0 strong buy ratings
  • 13 buy ratings
  • 5 hold ratings
  • 1 sell ratings
8/28/2023
  • 0 strong buy ratings
  • 13 buy ratings
  • 5 hold ratings
  • 1 sell ratings
11/26/2023
  • 0 strong buy ratings
  • 13 buy ratings
  • 5 hold ratings
  • 1 sell ratings
2/24/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 5 hold ratings
  • 1 sell ratings
4/24/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 5 hold ratings
  • 1 sell ratings
5/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 13 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/22/2024CitigroupUpgradeNeutral ➝ Buy$98.00 ➝ $105.00Low
5/14/2024Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$86.00 ➝ $103.00Low
5/7/2024BarclaysBoost TargetOverweight ➝ Overweight$100.00 ➝ $101.00Low
4/26/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$94.00 ➝ $99.00Low
4/26/2024Evercore ISILower TargetIn-Line ➝ In-Line$92.00 ➝ $89.00Low
4/26/2024Stifel NicolausBoost TargetHold ➝ Hold$83.00 ➝ $85.00Low
4/26/2024Piper SandlerBoost TargetNeutral ➝ Neutral$85.00 ➝ $88.00Low
4/15/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$95.00 ➝ $101.00Low
4/11/2024MizuhoBoost TargetBuy ➝ Buy$95.00 ➝ $105.00Low
4/4/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$86.00 ➝ $92.00Low
4/3/2024CitigroupBoost TargetNeutral ➝ Neutral$90.00 ➝ $98.00Low
3/26/2024OTR GlobalUpgradeMixed ➝ PositiveLow
3/21/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$95.00 ➝ $103.00Low
3/18/2024OppenheimerBoost TargetOutperform ➝ Outperform$93.00 ➝ $100.00Low
3/7/2024Bank of AmericaUpgradeNeutral ➝ BuyLow
2/7/2024Stifel NicolausBoost TargetHold ➝ Hold$70.00 ➝ $83.00Low
2/7/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$80.00 ➝ $95.00Low
2/7/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$82.00 ➝ $95.00Low
2/7/2024MizuhoBoost TargetBuy ➝ Buy$85.00 ➝ $95.00Low
2/2/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$94.00Low
1/12/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$80.00 ➝ $82.00Low
1/4/2024Evercore ISIDowngradeOutperform ➝ In-Line$80.00 ➝ $77.00Low
12/22/2023Truist FinancialBoost TargetBuy ➝ Buy$78.00 ➝ $84.00Low
12/11/2023Truist FinancialBoost TargetBuy ➝ Buy$76.00 ➝ $78.00Low
12/11/2023CitigroupDowngradeBuy ➝ NeutralLow
12/4/2023Morgan StanleyLower TargetOverweight ➝ Overweight$102.00 ➝ $80.00Low
11/28/2023Wolfe ResearchDowngradePeer Perform ➝ Underperform$57.00Low
10/26/2023Stifel NicolausLower TargetHold ➝ Hold$87.00 ➝ $70.00Low
10/26/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$86.00 ➝ $82.00Low
10/26/2023Truist FinancialLower TargetBuy ➝ Buy$83.00 ➝ $76.00Low
10/26/2023MizuhoLower TargetBuy ➝ Buy$90.00 ➝ $85.00Low
10/26/2023Piper SandlerLower TargetNeutral ➝ Neutral$83.00 ➝ $68.00Low
10/26/2023CitigroupLower TargetBuy ➝ Buy$94.00 ➝ $85.00Low
10/26/2023Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$88.00 ➝ $75.00Low
10/16/2023Leerink PartnrsReiterated RatingMarket PerformLow
10/16/2023SVB LeerinkInitiated CoverageMarket Perform$75.00Low
10/2/2023CitigroupLower TargetBuy ➝ Buy$110.00 ➝ $94.00Low
9/26/2023OppenheimerUpgradeMarket Perform ➝ Outperform$90.00Low
9/8/2023Piper SandlerLower TargetNeutral ➝ Neutral$88.00 ➝ $83.00Low
8/17/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$96.00Low
8/1/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$96.00Low
7/27/2023Piper SandlerBoost Target$83.00 ➝ $88.00Low
7/25/2023Jefferies Financial GroupBoost TargetBuy$103.00 ➝ $107.00Low
7/19/2023Truist FinancialBoost Target$101.00 ➝ $105.00Low
7/18/2023Robert W. BairdInitiated CoverageOutperform$107.00Low
7/17/2023MizuhoBoost Target$95.00 ➝ $102.00Low
7/14/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$102.00Low
7/10/2023CitigroupBoost Target$101.00 ➝ $110.00Low
6/27/202358.comReiterated RatingReiteratesLow
5/30/2023Morgan StanleyInitiated CoverageOverweight$102.00Low
5/18/2023Truist FinancialBoost Target$97.00 ➝ $101.00Low
4/28/2023BarclaysBoost Target$94.00 ➝ $102.00Low
4/27/2023Wells Fargo & CompanyBoost Target$78.00 ➝ $90.00Low
4/27/2023Piper SandlerBoost Target$80.00 ➝ $83.00Low
4/27/2023Truist FinancialBoost Target$93.00 ➝ $97.00Low
4/25/2023MizuhoBoost Target$85.00 ➝ $95.00Low
4/24/2023Stifel NicolausBoost Target$75.00 ➝ $87.00Low
4/17/2023Truist FinancialBoost TargetBuy$86.00 ➝ $93.00Low
4/3/2023CitigroupBoost TargetBuy$92.00 ➝ $97.00Low
3/28/2023UBS GroupInitiated CoverageNeutral$84.00Low
3/8/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$97.00 ➝ $78.00N/A
2/6/2023Raymond JamesDowngradeOutperform ➝ Market PerformLow
2/1/2023Canaccord Genuity GroupBoost TargetHold$68.00 ➝ $76.00Low
2/1/2023Truist FinancialBoost TargetBuy$85.00 ➝ $86.00Low
1/31/2023Sanford C. BernsteinDowngradeOutperform ➝ Underperform$95.00 ➝ $66.00Low
1/30/2023Piper SandlerDowngradeOverweight ➝ Neutral$95.00 ➝ $80.00Low
1/6/2023Morgan StanleyBoost TargetOverweight$92.00 ➝ $95.00Low
12/13/2022Raymond JamesLower TargetOutperform$85.00 ➝ $83.00Low
12/12/2022Canaccord Genuity GroupLower TargetHold ➝ Hold$78.00 ➝ $73.00Low
12/12/2022CitigroupLower TargetBuy$99.00 ➝ $92.00Low
12/9/2022Morgan StanleyLower Target$98.00 ➝ $92.00Low
12/7/2022MizuhoLower TargetBuy$100.00 ➝ $85.00Low
12/5/2022Stifel NicolausDowngradeBuy ➝ Hold$95.00 ➝ $75.00Low
12/1/2022Wolfe ResearchDowngradeOutperform ➝ Market PerformLow
11/28/2022Royal Bank of CanadaLower TargetOutperform$118.00 ➝ $105.00Low
11/3/2022The Goldman Sachs GroupLower TargetNeutral$97.00 ➝ $73.00Low
10/31/2022Raymond JamesLower TargetOutperform$120.00 ➝ $85.00Low
10/28/2022Royal Bank of CanadaLower TargetOutperform$128.00 ➝ $118.00Low
10/28/2022Morgan StanleyLower TargetOverweight$108.00 ➝ $98.00Low
10/28/2022Wells Fargo & CompanyLower TargetOverweight$121.00 ➝ $93.00Low
10/28/2022Truist FinancialLower TargetBuy$112.00 ➝ $95.00Low
10/28/2022CowenLower Target$125.00 ➝ $100.00Low
10/28/2022CowenLower Target$125.00 ➝ $100.00Low
10/28/2022Deutsche Bank AktiengesellschaftLower Target$113.00 ➝ $83.00Low
10/28/2022CitigroupLower TargetBuy$107.00 ➝ $99.00Low
10/28/2022OppenheimerDowngradeOutperform ➝ Market PerformLow
10/28/2022Piper SandlerLower TargetOverweight$120.00 ➝ $95.00N/A
10/26/2022MizuhoInitiated CoverageBuy$100.00Low
10/17/2022BarclaysInitiated CoverageOverweight$96.00Low
10/14/2022Canaccord Genuity GroupLower Target$106.00 ➝ $91.00Low
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$110.00Low
10/11/2022Morgan StanleyLower TargetOverweight$119.00 ➝ $108.00Low
10/5/2022CitigroupLower Target$118.00 ➝ $107.00Low
9/22/2022Truist FinancialLower TargetBuy$117.00 ➝ $112.00Low
7/29/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$115.00 ➝ $106.00Low
7/20/2022Truist FinancialLower TargetBuy$140.00 ➝ $120.00Low
7/18/2022Stifel NicolausLower Target$128.00 ➝ $115.00Low
7/15/2022Morgan StanleyLower TargetOverweight$136.00 ➝ $119.00Low
7/11/2022CowenLower Target$140.00 ➝ $125.00N/A
7/11/2022CowenLower Target$140.00 ➝ $125.00N/A
5/17/2022CitigroupLower TargetBuy$134.00 ➝ $115.00N/A
4/27/2022Canaccord Genuity GroupLower Target$152.00 ➝ $137.00High
4/27/2022CitigroupLower Target$138.00 ➝ $134.00High
4/26/2022William BlairReiterated RatingOutperformLow
4/12/2022Truist FinancialInitiated CoverageBuy$145.00Low
4/5/2022Wolfe ResearchInitiated CoverageOutperform$134.00Low
3/16/2022Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$132.00 ➝ $135.00Low
3/1/2022Bank of AmericaInitiated CoverageNeutral ➝ NeutralLow
2/2/2022UBS GroupUpgradeNeutral ➝ Buy$121.00 ➝ $126.00Low
1/27/2022Evercore ISILower TargetOutperform$130.00 ➝ $122.00High
1/27/2022UBS GroupLower TargetNeutral$125.00 ➝ $121.00High
1/27/2022CitigroupLower TargetBuy$142.00 ➝ $138.00High
1/27/2022Stifel NicolausLower TargetBuy$132.00 ➝ $120.00High
1/27/2022Morgan StanleyLower TargetOverweight$148.00 ➝ $136.00High
1/27/2022Raymond JamesLower TargetOutperform$134.00 ➝ $126.00High
1/27/2022Piper SandlerLower Target$133.00 ➝ $125.00High
1/21/2022SVB LeerinkLower TargetOutperform$135.00 ➝ $132.00High
1/7/2022Credit Suisse GroupBoost TargetOutperform$131.00 ➝ $144.00Low
1/7/2022Morgan StanleyBoost TargetOverweight$144.00 ➝ $148.00Medium
12/17/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$114.00 ➝ $140.00High
12/15/2021CitigroupUpgradeNeutral ➝ Buy$120.00 ➝ $142.00Medium
12/10/2021Raymond JamesBoost TargetOutperform ➝ Outperform$127.00 ➝ $134.00Low
12/9/2021Royal Bank of CanadaInitiated CoverageOutperform$142.00Low
12/9/2021Morgan StanleyBoost TargetOverweight$135.00 ➝ $144.00Medium
12/9/2021SVB LeerinkBoost TargetOutperform$130.00 ➝ $135.00Low
12/8/2021Piper SandlerBoost TargetOverweight ➝ Overweight$123.00 ➝ $133.00Low
12/6/2021Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$126.00High
10/29/2021Jefferies Financial GroupBoost TargetBuy$130.00 ➝ $135.00High
10/28/2021Credit Suisse GroupBoost TargetOutperform$126.00 ➝ $130.00High
10/28/2021Wells Fargo & CompanyBoost TargetEqual Weight$115.00 ➝ $126.00High
10/28/2021Raymond JamesBoost TargetOutperform$122.00 ➝ $127.00High
10/28/2021CitigroupBoost TargetNeutral$113.00 ➝ $120.00High
8/3/2021The Goldman Sachs GroupBoost TargetNeutral$93.00 ➝ $105.00Low
8/2/2021Raymond JamesBoost TargetOutperform$101.00 ➝ $122.00Low
7/30/2021Credit Suisse GroupBoost TargetOutperform$112.00 ➝ $126.00High
7/30/2021Morgan StanleyBoost TargetOverweight$108.00 ➝ $135.00High
7/30/2021OppenheimerBoost TargetOutperform$97.00 ➝ $120.00High
7/30/2021Stifel NicolausBoost TargetBuy$103.00 ➝ $120.00High
7/30/2021UBS GroupBoost TargetNeutral$98.00 ➝ $115.00High
7/30/2021SVB LeerinkBoost TargetOutperform$125.00 ➝ $130.00Medium
7/30/2021Jefferies Financial GroupBoost TargetBuy$110.00 ➝ $130.00High
7/30/2021Wells Fargo & CompanyBoost TargetEqual Weight$93.00 ➝ $115.00High
7/30/2021Deutsche Bank AktiengesellschaftBoost TargetHold$84.00 ➝ $113.00High
7/27/2021Piper SandlerBoost TargetOverweight$105.00 ➝ $120.00Low
7/23/2021CowenBoost TargetOutperform$100.00 ➝ $125.00Low
7/20/2021SVB LeerinkBoost TargetOutperform$106.00 ➝ $125.00Low
5/24/2021BarclaysInitiated CoverageOverweight$110.00Low
4/21/2021Morgan StanleyBoost TargetOverweight$99.00 ➝ $108.00High
4/21/2021Raymond JamesBoost TargetOutperform$96.00 ➝ $101.00High
4/21/2021Wells Fargo & CompanyBoost TargetEqual Weight$87.00 ➝ $93.00High
4/21/2021Piper SandlerBoost TargetOverweight$97.00 ➝ $105.00High
4/15/2021Atlantic SecuritiesInitiated CoverageNeutral$85.00Low
4/5/2021Evercore ISIUpgradeIn-Line ➝ OutperformMedium
12/16/2020Smith Barney CitigroupDowngradeBuy ➝ NeutralLow
12/14/2020Morgan StanleyBoost TargetOverweight$88.00 ➝ $99.00Medium
12/11/2020Raymond JamesBoost TargetOutperform$90.00 ➝ $96.00Low
12/11/2020Piper SandlerBoost TargetOverweight$93.00 ➝ $98.00High
12/11/2020SVB LeerinkBoost TargetOutperform$100.00 ➝ $106.00High
12/7/2020Credit Suisse GroupBoost Target$97.00 ➝ $111.00Medium
11/18/2020Wells Fargo & CompanyBoost TargetEqual Weight$84.00 ➝ $87.00Low
10/27/2020Jefferies Financial GroupBoost TargetBuy$95.00 ➝ $105.00Medium
10/22/2020Credit Suisse GroupBoost TargetOutperform$92.00 ➝ $97.00High
10/22/2020Raymond JamesBoost TargetOutperform$88.00 ➝ $90.00High
10/19/2020CowenBoost TargetOutperform$85.00 ➝ $100.00Medium
10/14/2020Piper SandlerBoost TargetOverweight$91.00 ➝ $93.00Low
10/12/2020SVB LeerinkBoost TargetOutperform$95.00 ➝ $100.00Low
9/11/2020Wolfe ResearchInitiated CoverageUnderperformLow
7/24/2020Stifel NicolausBoost TargetBuy$85.00 ➝ $90.00Low
7/24/2020Jefferies Financial GroupBoost TargetBuy$87.00 ➝ $95.00Low
7/24/2020Credit Suisse GroupBoost TargetOutperform$88.00 ➝ $92.00High
7/24/2020Morgan StanleyBoost TargetOverweight$83.00 ➝ $88.00High
7/24/2020SVB LeerinkBoost TargetOutperform$90.00 ➝ $95.00High
7/24/2020Raymond JamesBoost TargetOutperform$83.00 ➝ $88.00High
7/24/2020Piper SandlerBoost TargetPositive ➝ Overweight$88.00 ➝ $91.00High
7/13/2020OppenheimerInitiated CoverageBuy$93.00High
6/29/2020Morgan StanleyLower TargetOverweight$83.33 ➝ $83.00Low
6/2/2020Credit Suisse GroupLower TargetOutperform$88.00High
6/1/2020Morgan StanleyLower TargetOverweight$83.33 ➝ $83.00N/A
4/28/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$83.33 ➝ $76.67High
4/27/2020BarclaysReiterated RatingUnderweight$55.00 ➝ $51.67High
4/24/2020CfraBoost TargetBuy$67.00 ➝ $77.00Low
4/24/2020Raymond JamesBoost TargetOutperform$76.67 ➝ $83.33Low
4/24/2020Stifel NicolausBoost TargetBuy$76.67 ➝ $85.00Low
4/24/2020Piper SandlerLower TargetOverweight$90.00 ➝ $88.33Low
4/24/2020Morgan StanleyBoost TargetOverweight$80.33 ➝ $83.33High
4/24/2020Credit Suisse GroupBoost TargetOutperform$86.67 ➝ $87.33High
4/24/2020Wells Fargo & CompanyBoost TargetOverweight$71.67 ➝ $83.33High
4/24/2020CitigroupBoost TargetBuy$80.00 ➝ $85.00High
4/23/2020BTIG ResearchReiterated RatingHoldHigh
4/22/2020Deutsche Bank AktiengesellschaftLower TargetHold$81.67 ➝ $75.00Low
4/20/2020CowenLower TargetTop Pick ➝ Outperform$91.67 ➝ $83.33Medium
4/19/2020SVB LeerinkDowngradeOutperform ➝ Market PerformMedium
4/17/2020SVB LeerinkUpgradeMarket Perform ➝ Outperform$90.00High
4/9/2020Raymond JamesLower TargetOutperform$87.67 ➝ $76.67High
4/6/2020Wells Fargo & CompanyLower TargetOverweight$90.67 ➝ $71.67Low
3/27/2020Morgan StanleyLower TargetOverweight$90.00 ➝ $80.33Low
3/27/2020CitigroupLower TargetBuy$84.00 ➝ $80.00Low
3/13/2020CfraUpgradeSell ➝ Hold$69.00 ➝ $67.00High
3/6/2020Credit Suisse GroupLower TargetOutperform$92.67 ➝ $89.00Low
3/4/2020CitigroupInitiated CoverageBuy$84.00Low
2/12/2020The Goldman Sachs GroupInitiated CoverageNeutral$84.33Low
2/6/2020BTIG ResearchInitiated CoverageHoldMedium
1/31/2020CfraBoost TargetSell$68.33 ➝ $69.00High
1/31/2020Stifel NicolausBoost TargetBuy$91.67 ➝ $93.33High
1/31/2020Wells Fargo & CompanyBoost TargetOverweight$90.00 ➝ $90.67High
1/31/2020Deutsche Bank AktiengesellschaftBoost TargetHold$78.67 ➝ $81.67High
1/31/2020Credit Suisse GroupBoost TargetOutperform$91.67 ➝ $92.67High
1/31/2020Piper SandlerBoost TargetOverweight$87.33 ➝ $90.00High
1/31/2020UBS GroupBoost TargetNeutral$85.00 ➝ $86.67High
1/9/2020OppenheimerUpgradeMarket Perform ➝ Buy$93.33Medium
1/3/2020Deutsche Bank AktiengesellschaftInitiated CoverageHold$54.67Low
12/17/2019CowenReiterated RatingBuy$91.67Medium
12/9/2019Piper Sandler CompaniesBoost TargetOverweight$85.00 ➝ $87.33High
12/6/2019UBS GroupBoost TargetNeutral$83.33 ➝ $85.00High
12/6/2019Wells Fargo & CompanyBoost TargetOutperform$87.33 ➝ $90.00High
12/6/2019Credit Suisse GroupBoost TargetOutperform$89.67 ➝ $91.67High
12/6/2019Morgan StanleyBoost TargetOverweight$82.67 ➝ $90.00High
12/6/2019Raymond JamesBoost TargetOutperform$85.00 ➝ $87.67High
12/3/2019Jefferies Financial GroupBoost TargetBuy$85.00 ➝ $95.00Low
10/24/2019Raymond JamesBoost TargetOutperform$83.33 ➝ $85.00High
10/24/2019CowenBoost TargetOutperform ➝ Positive$83.33 ➝ $88.33High
10/24/2019Wells Fargo & CompanyBoost TargetOutperform$83.33 ➝ $87.33High
10/24/2019Piper Sandler CompaniesBoost TargetOverweight$80.00 ➝ $85.00High
10/22/2019Royal Bank of CanadaBoost TargetBuy ➝ Outperform$72.33 ➝ $83.33Medium
10/16/2019UBS GroupBoost TargetNeutral$68.33 ➝ $76.67Low
10/14/2019Raymond JamesBoost TargetOutperform$77.33 ➝ $83.33Low
10/14/2019Credit Suisse GroupBoost TargetPositive ➝ Outperform$75.33 ➝ $87.00Low
9/23/2019Piper Sandler CompaniesInitiated CoverageOverweight$80.00 ➝ $80.00Low
9/6/2019Wells Fargo & CompanyBoost TargetOutperform$73.33 ➝ $83.33Low
7/26/2019CitigroupSet TargetSell$53.00Low
7/25/2019BTIG ResearchReiterated RatingHoldLow
7/24/2019BMO Capital MarketsBoost TargetOutperform$68.00 ➝ $74.67Low
7/24/2019JPMorgan Chase & Co.Boost TargetNeutral$63.33 ➝ $75.00Low
7/24/2019Bank of AmericaReiterated RatingBuy ➝ Buy$71.67 ➝ $75.00Low
7/24/2019Wells Fargo & CompanyBoost TargetOutperform$69.00 ➝ $73.33High
7/24/2019Morgan StanleyBoost TargetOverweight$70.00 ➝ $76.00High
7/24/2019Raymond JamesBoost TargetOutperform$66.67 ➝ $77.33High
7/24/2019BarclaysBoost TargetUnderweight$53.33 ➝ $58.33High
7/24/2019Credit Suisse GroupBoost TargetOutperform$73.67 ➝ $75.33High
7/24/2019Jefferies Financial GroupBoost TargetBuy$70.00 ➝ $81.67High
7/16/2019Morgan StanleyBoost TargetOverweight$65.67 ➝ $70.00Medium
(Data available from 5/24/2019 forward)

News Sentiment Rating

0.98 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 29 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
10/27/2023
  • 8 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/26/2023
  • 26 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
12/26/2023
  • 26 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/25/2024
  • 42 very positive mentions
  • 35 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
2/24/2024
  • 35 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2024
  • 36 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/24/2024
  • 45 very positive mentions
  • 32 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/24/2024

Current Sentiment

  • 45 very positive mentions
  • 32 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Edwards Lifesciences logo
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $88.22
Low: $87.31
High: $88.32

50 Day Range

MA: $89.77
Low: $84.23
High: $95.56

52 Week Range

Now: $88.22
Low: $60.57
High: $96.12

Volume

453,826 shs

Average Volume

3,536,874 shs

Market Capitalization

$53.16 billion

P/E Ratio

38.03

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Edwards Lifesciences?

The following equities research analysts have issued reports on Edwards Lifesciences in the last twelve months: 58.com Inc., Bank of America Co., Barclays PLC, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Evercore ISI, Jefferies Financial Group Inc., Leerink Partnrs, Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., OTR Global, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, TheStreet, Truist Financial Co., Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for EW.

What is the current price target for Edwards Lifesciences?

16 Wall Street analysts have set twelve-month price targets for Edwards Lifesciences in the last year. Their average twelve-month price target is $94.31, suggesting a possible upside of 7.8%. Robert W. Baird has the highest price target set, predicting EW will reach $107.00 in the next twelve months. Wolfe Research has the lowest price target set, forecasting a price of $57.00 for Edwards Lifesciences in the next year.
View the latest price targets for EW.

What is the current consensus analyst rating for Edwards Lifesciences?

Edwards Lifesciences currently has 1 sell rating, 5 hold ratings and 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for EW.

What other companies compete with Edwards Lifesciences?

Other companies that are similar to Edwards Lifesciences include STERIS, Intuitive Surgical, Zimmer Biomet, Align Technology and Moderna. Learn More about companies similar to Edwards Lifesciences.

How do I contact Edwards Lifesciences' investor relations team?

Edwards Lifesciences' physical mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company's listed phone number is (949) 250-2500 and its investor relations email address is [email protected]. The official website for Edwards Lifesciences is www.edwards.com. Learn More about contacing Edwards Lifesciences investor relations.